GPP
XLRN

Great Point Partners’s Acceleron Pharma XLRN Stock Holding History

Great Point Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-552,300
Closed -$26.8M – 44
2018
Q2 		$26.8M Buy
+552,300
New +$20.1M 3.71% 12

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Great Point Partners's XLRN Position: Q3 2020 in Review

Great Point Partners sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 58,056 shares — an estimated $5.53M sold.

Great Point Partners first reported a position in XLRN in Q1 2017 and held it in 14 quarters. The position peaked at $59.5M in Q2 2019. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

  • Great Point Partners reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
  • Great Point Partners sold 58,056 Acceleron Pharma shares in Q3 2020, an estimated $5.53M.
  • Great Point Partners first reported a position in Acceleron Pharma in Q1 2017 and held it in 14 quarters.
  • Great Point Partners's Acceleron Pharma position peaked at $59.5M in Q2 2019.
  • 238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Great Point Partners's 13F filing for Q3 2020, filed 16 Nov 2020.